Precision Biologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Precision Biologics is a private, clinical-stage biotech founded in 2014 and headquartered in Rockville, MD, with an additional office in Bethesda. The company's core asset is a proprietary library of patient tumor-derived cancer vaccines and antigens, originally developed by immunotherapy pioneer Dr. Ariel Hollinshead. This platform enables the discovery of novel, tumor-specific targets for the development of monoclonal antibodies and ADCs, positioning the company in the targeted oncology space with a focus on both therapeutics and companion diagnostics. Leadership is anchored by CEO Dr. Philip M. Arlen, who continues the scientific legacy of his father, Dr. Myron Arlen.

Oncology

Technology Platform

Proprietary discovery platform based on a historic library of patient tumor-derived cancer vaccines, antibodies, and tumor-associated antigens (from Dr. Ariel Hollinshead). The platform is used to identify novel, tumor-specific targets for monoclonal antibody and antibody-drug conjugate (ADC) development.

Opportunities

The company's unique, clinically-validated antigen library provides a potentially de-risked starting point for discovering novel, tumor-specific targets, a major unmet need in oncology.

Successfully developing an ADC with high tumor specificity could capture significant value in the large and growing targeted cancer therapy market, with companion diagnostics creating an additional revenue stream and commercial moat.

Risk Factors

Key risks include the high failure rate of drug development, where promising preclinical data may not translate to human efficacy, and financial dependency on private funding in a competitive capital environment.

The company also faces intense competition in the ADC space from larger, better-resourced entities and must successfully secure strong IP for its discoveries.

Competitive Landscape

Precision Biologics competes in the crowded and rapidly evolving field of targeted oncology, specifically against numerous biotech and pharma companies developing monoclonal antibodies and ADCs. Its differentiation hinges on the novelty and tumor-specificity of its targets derived from its unique historical library, competing on scientific innovation rather than resource scale.

More companies in Biologics / Biosimilars →More companies in United States →